How pharmaceutical pricing and reimbursement work in Switzerland

Key takeaways

• Swissmedic market authorisation does not automatically create reimbursement.
• Specialities List inclusion is based on effectiveness, appropriateness and economic efficiency.
• Economic assessment uses a therapeutic comparison and an external comparison across nine reference countries.
• Indication wording, limitations, evidence, price and launch sequence must be developed as one plan.

Which Swiss decision does each authority make?

Swissmedic assesses quality, safety and efficacy for market authorisation. FOPH manages the Specialities List, or SL, for medicines reimbursed in the outpatient sector by compulsory health insurance. FOPH evaluates effectiveness, appropriateness and economic efficiency, often abbreviated EAE in English or WZW in German, and sets the maximum price reimbursed by insurers.

Treat the two submissions as connected workstreams. The proposed indication, population, comparator evidence, pack and product information used in regulatory planning shape the reimbursement case. Authorisation permits commercialisation, while routine outpatient reimbursement generally depends on an SL listing and compliance with any published limitation.

• Map Swissmedic and FOPH milestones separately
• Reconcile indication and population across dossiers
• Assign one owner for cross-workstream changes

Sources and further reading: [1][2]

What evidence supports a Specialities List application?

The reimbursement case must show why the medicine is effective in the proposed reimbursed population, appropriate for Swiss clinical use and economically efficient. Build an evidence map covering pivotal results, relevant outcomes, treatment pathway, comparator choice, dosing, duration, pack sizes, utilisation assumptions and the requested limitation. Identify what is established by the authorisation dossier and what needs specific health-insurance reasoning.

Evidence quality matters, but so does alignment. If the clinical evidence, requested wording, model assumptions and price file describe different populations or treatment positions, review questions become harder to resolve. Our suggested working method is a single claims-and-evidence table that records each proposed statement, its source, owner, language and use in the regulatory, reimbursement and price materials.

• Define the reimbursed population and treatment position
• Link every value claim to a source
• Align dosing, duration and pack assumptions
• Predefine answers to material evidence gaps

Sources and further reading: [1][4]

How is economic efficiency and price assessed?

FOPH describes two legally specified comparison components. The therapeutic comparison examines prices of medicines already reimbursed for the same indication. The external comparison considers the same medicine in nine reference countries: Austria, Belgium, Denmark, Finland, France, Germany, the Netherlands, Sweden and the United Kingdom. Conditions and requirements may also be set to maintain EAE compliance.

A price strategy should therefore document comparator selection, presentations, doses, treatment duration, foreign ex-factory evidence, exchange and date conventions, and scenarios for changes in the comparator set. Exact calculations must use the current rules and application materials. A planning model is useful for negotiation ranges, but it should never be presented as a guaranteed FOPH outcome.

Sources and further reading: [1]

How do limitations change the commercial outcome?

An SL entry can include a limitation on indication, patient group, treatment sequence, prescriber, quantity or other conditions. The reimbursed maximum price alone therefore does not describe access. Teams must read the listing text and any linked implementation documents, then translate them into field, medical, supply and forecast rules.

Model at least three cases: requested wording, a narrower reimbursed population and a delayed or no listing case. This is a commercial planning method, not a prediction of the authority decision. It helps expose whether pack strategy, evidence generation, patient identification or contractual assumptions still work if access is more restricted than the base case.

• Draft operational interpretations of proposed limitations
• Test eligible-patient identification
• Align forecasts with each access scenario
• Keep promotional use within the authorised indication

Sources and further reading: [2][4]

Where do individual-case reimbursement and early routes fit?

Individual-case reimbursement is an exception pathway, not a substitute for an SL strategy. FOPH explains that compulsory insurance may reimburse certain uses outside an SL limitation or authorised indication, authorised medicines not listed in the SL, and some imported unapproved medicines, if the applicable conditions are met. The treating physician submits the request to the insurer before treatment, and the insurer assesses the case.

Parallel or coordinated regulatory and reimbursement routes may be available in particular situations, and FOPH notes measures that can permit reimbursement at the time of Swissmedic authorisation for certain medicines. Eligibility and outcome are never automatic. Confirm the current route, required status and dossier sequence for the specific product before building a launch promise around it.

• Keep exceptional access separate from routine listing
• Define who supplies evidence for an individual case
• Verify eligibility for any coordinated route
• Avoid promising timing or reimbursement outcome

Sources and further reading: [1][3]

How should a company choose its launch sequence and adviser?

Start with a decision memo: target indication, Swissmedic status, intended SL scope, evidence maturity, likely therapeutic comparators, reference-country status, pack plan and acceptable access scenarios. Then identify the capability gap. Regulatory writing, health economics, Swiss price-file preparation, payer strategy and legal review are different services and may require more than one specialist.

When comparing advisers, ask for a product-specific workplan, assumptions register, review governance, language capability, conflicts process and clear boundaries between strategic advice and submission execution. We can review a non-confidential enquiry and discuss a possible specialist introduction first. Any regulated or professional engagement would be agreed directly with the selected provider.

• Ask who owns each submission and calculation
• Request assumptions and evidence traceability
• Define review and authority-question governance
• Separate informative scoping from professional advice

Sources and further reading: [1][2]